ziftomenib

{
  "id": "MLC-T-ONC-017664",
  "term": "ziftomenib",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) fusion protein, with potential antineoplastic activity. Upon oral administration, ziftomenib prevents the interaction between the two proteins menin and MLL, and thus the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth and proliferation of certain kinds of leukemia cells.",
  "synonyms": [
    "menin-KMT2A inhibitor KO 539",
    "menin-mixed lineage leukemia protein-protein interaction inhibitor KO 539",
    "menin-MLL inhibitor KO-539",
    "menin-MLL interaction inhibitor KO 539"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ziftomenib/"
}